Trazodone

Introduction Overview

Generic Name

trazodone

Brand Name

Desyrel, Desyrel Dividose, Oleptro, Raldesy

Dosage Form

oral tablet (50 mg, 100 mg, 150 mg, 300 mg), oral solution (10 mg/mL)

Drug Class

Phenylpiperazine antidepressants

Pharmacokinetics

Absorption:
Trazodone exhibits rapid and extensive absorption from the gastrointestinal tract following oral administration. Peak plasma concentrations are typically observed within 1 to 2 hours after dosing. The absolute bioavailability is decreased due to significant first-pass hepatic metabolism. Food intake, especially fat-containing meals, can increase trazodone’s bioavailability and delay its time to peak concentration. This can have clinical implications for onset of action and side-effect profiles. Clinical studies show that administering trazodone shortly after a light meal may optimize absorption while minimizing gastrointestinal discomfort.

Distribution:
Trazodone is widely distributed in body tissues and fluids, exhibiting a volume of distribution ranging between 1.9 and 2.7 L/kg. It is approximately 89-95% bound to plasma proteins, primarily albumin, which impacts its pharmacokinetic interactions with other highly protein-bound drugs. Due to its lipophilicity, trazodone readily crosses the blood-brain barrier to exert central nervous system effects. It also crosses the placental barrier and is detected in breast milk, which should be considered when prescribing to pregnant or lactating patients.

Metabolism:
Trazodone undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme system, predominantly CYP3A4. The major metabolic pathways include oxidative N-dealkylation to m-chlorophenylpiperazine (m-CPP), an active metabolite with serotonergic effects, and hydroxylation. The formation of active metabolites contributes to the drug's therapeutic and side effect profiles. Genetic polymorphisms or inhibitors/inducers of CYP3A4 can significantly influence trazodone metabolism, requiring dose adjustments. Metabolite activity and half-lives have also been studied to understand delayed or prolonged pharmacodynamic effects.

Elimination:
Trazodone and its metabolites are predominantly eliminated via renal excretion, with approximately 70% of the administered dose recovered in the urine, mostly as metabolites. The elimination half-life ranges between 5 to 13 hours, supporting once to twice daily dosing regimens depending on the formulation and clinical context. Hepatic and renal impairment can alter elimination kinetics, necessitating cautious dosing and monitoring. Biliary excretion is a minor elimination pathway. Studies highlight the importance of gradual dose titration and avoidance of abrupt discontinuation to minimize withdrawal phenomena.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 50 mg, 100 mg, 150 mg, 300 mg
- Oral solution: 10 mg/mL

Dosages for Adults and Adolescents:
- Initial dose for major depressive disorder (MDD): 150 mg per day administered orally in divided doses, typically two to three times daily.
- Dosage titration can proceed by increasing 50 mg every 3 to 4 days based on clinical response and tolerability.
- Maximum dose for inpatients is generally 600 mg per day; for outpatients, the maximum is 400 mg per day.
- After symptom improvement, gradual dosage reduction is recommended to maintain remission and minimize withdrawal symptoms.
- Dose adjustments may be required for patients experiencing excessive sedation by administering a larger portion of the daily dose at bedtime.

Specific Patient Populations:
- Elderly patients may require lower doses due to increased sensitivity and altered pharmacokinetics.
- Patients with hepatic or renal impairment should be dosed cautiously as metabolism and elimination may be decreased.
- Not approved for use in individuals under 18 years due to lack of safety and efficacy data.
- Pregnant and lactating women require careful risk-benefit assessment; trazodone may cross placenta and appear in breast milk.
- Use in patients with cardiovascular risks (e.g., long QT syndrome) should be carefully evaluated, with ECG monitoring when indicated.

Clinical Guidelines:
- Trazodone is taken after meals or a snack to optimize absorption and reduce gastrointestinal adverse effects.
- It is crucial to avoid abrupt discontinuation to prevent withdrawal symptoms; slow tapering is advisable.
- Clinicians should monitor for emergence or worsening of suicidal ideation, especially during initial treatment phases.

Mechanism Of Action

Trazodone’s primary mechanism of action is its function as a serotonin receptor antagonist and reuptake inhibitor (SARI). Unlike selective serotonin reuptake inhibitors (SSRIs), trazodone not only inhibits the reuptake of serotonin by blocking serotonin transporters (SERT), enhancing serotonergic neurotransmission, but also antagonizes specific serotonin receptor subtypes including 5-HT2A and 5-HT2C receptors. This antagonism is thought to ameliorate some of the adverse effects commonly associated with SSRIs, such as sexual dysfunction and anxiety, and to promote downstream therapeutic benefits.

At the cellular level, trazodone’s blockade of 5-HT2A receptors leads to modulation of glutamatergic transmission and downstream signaling pathways involved in neuroplasticity. This receptor antagonism reduces the excitatory effects mediated by serotonin and has been associated with anxiolytic and sleep-promoting properties, which complement its antidepressant effects. The drug also has mild antagonistic effects at alpha-1 adrenergic receptors, which may contribute to orthostatic hypotension risk, and histamine H1 receptors, contributing to its sedative profile.

Biochemically, the active metabolite m-chlorophenylpiperazine (m-CPP) has partial agonist activity at various serotonin receptors, which may modulate treatment responses and side effects. The combination of serotonin reuptake inhibition and receptor modulation results in a balanced serotonergic enhancement with a different therapeutic and side effect profile than conventional SSRIs.

Clinically, this mechanism translates into efficacy in major depressive disorder with additional benefits in alleviating anxiety and insomnia symptoms often comorbid with depression. Comparative studies suggest that trazodone’s mechanism affords sedative and anxiolytic benefits without strong anticholinergic effects, distinguishing it from other antidepressants. Ongoing research continues to explore trazodone’s impact on neurochemical systems and its utility in adjunctive treatment of various psychiatric and sleep disorders.

Pharmacological Actions

Selective inhibition of serotonin reuptake, enhancing serotonergic neurotransmission in the CNS.
Antagonism of 5-HT2A and 5-HT2C serotonin receptors, modulating downstream neurochemical effects.
Antagonistic effects on alpha-1 adrenergic receptors contributing to vasodilation and potential orthostatic hypotension.
Histamine H1 receptor antagonism leading to sedative and hypnotic activity.
Partial agonist activity of active metabolite m-chlorophenylpiperazine (m-CPP) impacting serotonergic balance.
Anxiolytic properties resulting from combined serotonergic modulation.
Sleep-promoting effects beneficial in patients with insomnia comorbid with depression.
Low anticholinergic activity contributing to a favorable side effect profile compared to tricyclic antidepressants.
Modulation of neuroplasticity-related intracellular signaling pathways enhancing long-term antidepressant efficacy.
Mild hypotensive effects due to vasodilatory properties derived from alpha-1 adrenergic blockade.
Rapid onset of sedative effects, aiding in amelioration of sleep disturbances.
Low potential for dependence or withdrawal compared to benzodiazepines.
Potential to improve appetite and energy levels in depressive states.
Minimal impact on monoamines other than serotonin, resulting in a targeted pharmacological profile.
Contributory role in modulating glutamatergic transmission via serotonin receptor blockade.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Management of anxiety symptoms associated with depression.
Adjunct therapy for insomnia, particularly when associated with depressive disorders.
Improvement of mood, appetite, and energy levels in depressive patients.
Off-label use in treatment of generalized anxiety disorder and post-traumatic stress disorder (PTSD).
Management of agitation and behavioral symptoms in elderly patients with depression.
Use as an alternative antidepressant in patients intolerant to SSRIs or tricyclic antidepressants.
Adjunct in chronic pain management where depression coexists.
Treatment of sleep disturbances in bipolar disorder during depressive phases, with caution.
Occasional use in the management of alcohol dependence-related insomnia.
Utilization in patients with depression complicated by insomnia where benzodiazepines are contraindicated.
Reduction of anxiety and insomnia symptoms to improve overall quality of life in depressed patients.
Potential off-label use for behavioral disturbances in dementia under clinical supervision.
Used in psychiatry for managing depressive symptoms with concurrent sleep dysfunction.
Employing trazodone’s sedative properties to minimize use of hypnotic agents and their associated risks.

Side Or Adverse Effects

Drowsiness and sedation, common especially at therapy initiation.
Dizziness and lightheadedness, particularly when standing up quickly (orthostatic hypotension).
Headache, reported in a subset of patients.
Dry mouth resulting from mild anticholinergic effects.
Nausea, vomiting, and gastrointestinal disturbances like diarrhea or constipation.
Blurred vision and visual disturbances.
Weight loss, occasionally noted during prolonged therapy.
Confusion or cognitive impairment, more frequent in elderly patients.
Priapism (prolonged, painful erections), a rare but serious adverse effect requiring immediate medical intervention.
QT interval prolongation with potential risk of arrhythmias, especially in predisposed individuals.
Serotonin syndrome when combined with other serotonergic agents.
Increased risk of bleeding or bruising with concomitant use of anticoagulants or NSAIDs.
Extrapyramidal symptoms, including tremors or agitation, rarely observed.
Withdrawal symptoms such as dizziness, sweating, agitation, and electric shock sensations upon abrupt discontinuation.
Allergic reactions, including rash, urticaria, and in rare cases, angioedema or anaphylaxis.

Precautions

Perform screening for personal or family history of bipolar disorder, mania, or hypomania before initiating therapy.
Monitor closely for emergence or worsening of suicidal ideation, particularly in young adults and during early treatment.
Use caution in patients with a history of cardiovascular disease, especially those with arrhythmias or prolonged QT interval.
Avoid abrupt discontinuation; taper doses gradually to prevent withdrawal symptoms.
Use with care in patients with hepatic or renal impairment due to altered metabolism and excretion.
Advise patients to rise slowly from sitting or lying positions to minimize orthostatic hypotension and falls.
Avoid concomitant use with monoamine oxidase inhibitors (MAOIs) and allow a 14-day washout period.
Exercise caution when prescribing to elderly patients due to increased risk of sedation, falls, and hyponatremia.
Monitor sodium levels, especially in elderly or patients on diuretics, to detect possible hyponatremia.
Screen and monitor for seizure disorders as trazodone may lower seizure threshold.
Advise patients against alcohol consumption due to additive CNS depressant effects and increased risk of overdose.
Use cautiously in patients with bleeding disorders or on anticoagulant therapy due to bleeding risk.
Assess for potential drug interactions, particularly with other CNS depressants and serotonergic agents.
Monitor mental status changes and behavioral symptoms regularly during treatment.
Pregnant and breastfeeding patients should be counseled on risks; assess benefits versus potential harm to the fetus or infant.

Warnings

Do not use trazodone in patients with known hypersensitivity to the drug or its components.
Contraindicated in patients currently taking or within 14 days of MAO inhibitor therapy due to risk of life-threatening serotonin syndrome.
Risk of serotonin syndrome when used concomitantly with other serotonergic agents, including SSRIs, SNRIs, tramadol, and herbal supplements like St. John's wort.
May increase risk of suicidal thoughts and behaviors, especially in children, adolescents, and young adults during initial treatment.
Patients should be monitored for severe hypotension, syncope, or arrhythmias; caution in those with cardiovascular disease.
Prolonged or painful penile erections (priapism) require immediate medical attention to prevent permanent damage.
CNS depression risk is increased with alcohol or other sedative drugs; avoid concomitant use.
Abrupt cessation can precipitate withdrawal symptoms; taper gradually under medical supervision.
Risk of bleeding complications increases with concomitant use of antiplatelet agents, anticoagulants, or NSAIDs.
Not approved for use in pediatric populations; safety and efficacy have not been established.
Potential for QT prolongation and associated torsades de pointes in predisposed individuals; use caution with other QT-prolonging drugs.
Use during pregnancy may pose risks to the fetus; consult healthcare provider for personalized risk assessment.
May cause impaired judgment or motor skills; patients should be warned about driving or operating machinery until effects are known.
Monitor for emergence of mania or hypomania in patients with bipolar disorder.
Severe allergic reactions, including anaphylaxis, though rare, require prompt management.

Contraindication

Known hypersensitivity to trazodone or any of its excipients.
Concurrent use or recent use (within 14 days) of monoamine oxidase inhibitors (MAOIs).
Use with methylene blue injection due to risk of severe drug interaction and serotonin syndrome.
Patients with a history of prolonged QT interval or other significant cardiac arrhythmias that predispose to torsades de pointes.
Use in children and adolescents under 18 years of age due to lack of safety and efficacy data.
Patients experiencing active bleeding or severe bleeding disorders without proper medical oversight.
Individuals with known history of priapism or conditions predisposing to priapism should avoid trazodone.
Severe hepatic impairment where metabolism and clearance are significantly compromised.
Concurrent use with other potent CYP3A4 inhibitors may be contraindicated without dose adjustment due to toxic accumulation.
Previous intolerance or severe adverse reaction to phenylpiperazine class antidepressants.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs): Risk of serotonin syndrome; contraindicated if used within 14 days.
Other serotonergic agents including SSRIs, SNRIs, triptans, tramadol, and St. John's wort increase serotonin syndrome risk.
CNS depressants such as benzodiazepines, opioids, muscle relaxants, and alcohol potentiate sedation and respiratory depression.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase trazodone plasma concentrations and toxicity risk.
CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce trazodone efficacy by enhancing metabolism.
Anticoagulants like warfarin may have increased bleeding risk when combined with trazodone.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can increase risk of bleeding when used concurrently.
Phenytoin levels may be altered by trazodone, necessitating monitoring of anticonvulsant levels.
Diuretics can predispose patients to hyponatremia when combined with trazodone.
Drugs prolonging QT interval may have additive effects increasing arrhythmia risk.
Certain antipsychotics used for mood disorders may interact and increase CNS effects or cardiac risks.
Concomitant use with sumatriptan or other migraine medications may increase serotonin syndrome risk.
Herbal supplements and vitamins may interact unpredictably; close monitoring is recommended.
Combining with tramadol increases risk of seizures and serotonin syndrome.
Additive hypotensive effects with other antihypertensives or alpha-blockers.

Preparations Of The Drug

Immediate-release oral tablets available in 50 mg, 100 mg, 150 mg, and 300 mg strengths.
Oral solution formulation at 10 mg/mL concentration for patients with swallowing difficulties or dose titration.
Extended-release formulations (e.g., Oleptro) designed to provide once-daily dosing and steady plasma levels.
Commercially available under brand names including Desyrel, Desyrel Dividose, Oleptro, and Raldesy.
Formulations contain inactive ingredients such as lactose, microcrystalline cellulose, and hypromellose to aid tablet formulation.
Packaging options include blister packs and bottles for tablets; bottles with calibrated droppers or measuring cups for oral solution.
Available as prescription-only preparations requiring healthcare provider supervision.
Generic formulations are widely available, providing cost-effective treatment options.
Some extended-release forms designed to minimize sedation and improve tolerability in outpatient settings.
Specialty formulations may include scored tablets for dosing flexibility.
Clinical compounding options may exist for patients with unique dosing or formulation needs.
Storage conditions involve room temperature, protected from moisture, heat, and light.
Proper dispensing information includes patient counseling on adherence and avoiding abrupt cessation.
Patient information leaflets provided with formulations to educate on side effects and precautions.
Preparation standards comply with regulatory agencies ensuring safety, efficacy, and quality.